SG11201804765UA - Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer - Google Patents
Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancerInfo
- Publication number
- SG11201804765UA SG11201804765UA SG11201804765UA SG11201804765UA SG11201804765UA SG 11201804765U A SG11201804765U A SG 11201804765UA SG 11201804765U A SG11201804765U A SG 11201804765UA SG 11201804765U A SG11201804765U A SG 11201804765UA SG 11201804765U A SG11201804765U A SG 11201804765UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- tarrytown
- antibodies
- saw mill
- river road
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111M 1111111111111111111111111111111111111111111111111111111111111R111111111111111 (10) International Publication Number WO 2017/112775 Al WIPOI PCT (43) International Publication Date 29 June 2017 (29.06.2017) Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). (74) Agents: BRUESS, Steven et al.; Merchant & Gould P.C., P.O. Box 2903, Minneapolis, MN 55402-0903 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KB, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2016/068030 (22) International Filing Date: 21 December 2016 (21.12.2016) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/270,749 22 December 2015 (22.12.2015) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). (72) Inventors: VARGHESE, Bindu; C/o Regeneron Pharma- ceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). THURSTON, Gavin; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). LOWY, Israel; C/o Regener- on Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). BROWNSTEIN, Carrie; C/o [Continued on next page] (54) Title: COMBINATION OF ANTI-PD-1 ANTIBODIES AND BISPECIFIC ANTI-CD20/ANTI-CD3 ANTIBODIES TO TREAT CANCER (57) : The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., a B-cell cancer such as Hodgkin's lymphoma or acute lymphoblastic leukemia). The methods of the present invention comprise administering to a subject in need thereof a therapeutically ef- fective amount of an antibody or anti- gen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specific- ally binds to CD20 and CD3. -40- Control - Vehicle r Isotype controls bsAbl RMPI-14 -to bsAb1 + RPMI 4000 E 3500 E 3000 2500 E CD 1500 4 .9 s en 2000 1000 500 0 -500 2 4 6 8 10 12 la 6 18 20 22 24 26 28 30 32 34 36 38 40 Days post implantation -1000 W O 20 17 / 112775 Al Figure 1 WO 2017/112775 V III SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270749P | 2015-12-22 | 2015-12-22 | |
| PCT/US2016/068030 WO2017112775A1 (en) | 2015-12-22 | 2016-12-21 | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804765UA true SG11201804765UA (en) | 2018-07-30 |
Family
ID=57799835
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202005670TA SG10202005670TA (en) | 2015-12-22 | 2016-12-21 | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
| SG11201804765UA SG11201804765UA (en) | 2015-12-22 | 2016-12-21 | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202005670TA SG10202005670TA (en) | 2015-12-22 | 2016-12-21 | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20170174779A1 (en) |
| EP (1) | EP3394103B1 (en) |
| JP (1) | JP7126941B2 (en) |
| KR (1) | KR20180089444A (en) |
| CN (1) | CN108473578A (en) |
| AU (1) | AU2016378721B2 (en) |
| BR (1) | BR112018012801B1 (en) |
| CA (1) | CA3009161A1 (en) |
| DK (1) | DK3394103T3 (en) |
| EA (1) | EA201891428A1 (en) |
| ES (1) | ES2954153T3 (en) |
| FI (1) | FI3394103T3 (en) |
| HK (1) | HK1255040A1 (en) |
| HR (1) | HRP20231156T1 (en) |
| HU (1) | HUE063377T2 (en) |
| IL (1) | IL259924A (en) |
| LT (1) | LT3394103T (en) |
| MA (1) | MA44146B1 (en) |
| MD (1) | MD3394103T2 (en) |
| MX (1) | MX2018007613A (en) |
| PL (1) | PL3394103T3 (en) |
| PT (1) | PT3394103T (en) |
| RS (1) | RS64588B1 (en) |
| SG (2) | SG10202005670TA (en) |
| SI (1) | SI3394103T1 (en) |
| WO (1) | WO2017112775A1 (en) |
| ZA (1) | ZA201804681B (en) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
| EP3954713A3 (en) | 2014-03-28 | 2022-03-30 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| BR112017011166A2 (en) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | heterodimeric antibodies that bind to cd3 and cd38 |
| CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| TWI822521B (en) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | Methods of treating skin cancer by administering a pd-1 inhibitor |
| TW201902512A (en) * | 2016-06-02 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | treatment method |
| MX2018015592A (en) | 2016-06-14 | 2019-04-24 | Xencor Inc | Bispecific checkpoint inhibitor antibodies. |
| CA3029328A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| KR102369014B1 (en) | 2016-08-16 | 2022-03-02 | 리제너론 파아마슈티컬스, 인크. | Methods for quantifying individual antibodies from mixtures |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| AU2017342559B2 (en) | 2016-10-14 | 2022-03-24 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments |
| PL3532838T3 (en) | 2016-10-25 | 2022-10-03 | Regeneron Pharmaceuticals, Inc. | Methods and systems for chromatography data analysis |
| BR112019010878A2 (en) * | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combination of multifunctional t-cell redirection antibodies with immune checkpoint modulators and their uses |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| US11225523B2 (en) | 2017-06-01 | 2022-01-18 | Compugen Ltd. | Triple combination antibody therapies |
| WO2018223004A1 (en) * | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
| JP2020529832A (en) | 2017-06-30 | 2020-10-15 | ゼンコア インコーポレイテッド | Targeted heterodimer Fc fusion protein containing IL-15 / IL-15Rα and antigen binding domain |
| CR20200099A (en) * | 2017-08-03 | 2020-07-24 | Amgen Inc | Interleukin-21 muteins and methods of treatment |
| SG11202001499WA (en) | 2017-09-08 | 2020-03-30 | Amgen Inc | Inhibitors of kras g12c and methods of using the same |
| KR20200086371A (en) * | 2017-09-20 | 2020-07-16 | 리제너론 파마슈티칼스 인코포레이티드 | The immunotherapy treatment about the patient having the tumor with high passenger gene mutation burden |
| EP3706793A1 (en) | 2017-11-08 | 2020-09-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| WO2019125732A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
| CR20200330A (en) | 2018-01-12 | 2020-12-23 | Amgen Inc | Anti-pd-1 antibodies and methods of treatment |
| JP7383620B2 (en) * | 2018-01-31 | 2023-11-20 | セルジーン コーポレイション | Combination therapy using adoptive cell therapy and checkpoint inhibitors |
| AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
| TW202005985A (en) * | 2018-06-21 | 2020-02-01 | 美商再生元醫藥公司 | Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies |
| TW202005694A (en) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | Systems and methods for preparing a polypeptide from a mixture |
| TWI822815B (en) * | 2018-07-14 | 2023-11-21 | 財團法人生物技術開發中心 | Anti- human pd-l1 antibodies and their uses |
| JP2022503959A (en) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | IL-12 heterodimer FC-fusion protein |
| AU2019369421A1 (en) | 2018-10-31 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| WO2020176699A1 (en) | 2019-02-28 | 2020-09-03 | Regeneron Pharmaceuticals, Inc. | Administration of pd-1 inhibitors for treating skin cancer |
| WO2020180726A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| KR20220030956A (en) | 2019-07-05 | 2022-03-11 | 오노 야꾸힝 고교 가부시키가이샤 | Hematological cancer treatment by PD-1/CD3 bispecific protein |
| BR112021025769A2 (en) | 2019-12-06 | 2022-04-12 | Regeneron Pharma | Anti-vegf protein compositions and methods for their production |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
| EP4222171A1 (en) * | 2020-10-02 | 2023-08-09 | Regeneron Pharmaceuticals, Inc. | Combination of antibodies for treating cancer with reduced cytokine release syndrome |
| EP3988568A1 (en) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
| WO2022165171A1 (en) | 2021-01-28 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| WO2022165275A2 (en) | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies |
| WO2022165266A1 (en) | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| CN114133449A (en) * | 2021-12-14 | 2022-03-04 | 厦门大学附属第一医院 | Antibody composition for detecting lymphocyte surface PD-1 receptor and application thereof |
| WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6808710B1 (en) | 1999-08-23 | 2004-10-26 | Genetics Institute, Inc. | Downmodulating an immune response with multivalent antibodies to PD-1 |
| JP4511943B2 (en) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Antibody against PD-1 and use thereof |
| LT2439273T (en) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| DK2170959T3 (en) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
| NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
| US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
| TWI682941B (en) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | Antibodies comprising chimeric constant domains |
| DK3083689T3 (en) * | 2013-12-17 | 2020-08-03 | Genentech Inc | Anti-CD3 antibodies and methods of use |
| TWI681969B (en) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| TWI701042B (en) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | Methods and antibody compositions for tumor treatment |
-
2016
- 2016-12-21 ES ES16826557T patent/ES2954153T3/en active Active
- 2016-12-21 SI SI201631733T patent/SI3394103T1/en unknown
- 2016-12-21 US US15/386,453 patent/US20170174779A1/en not_active Abandoned
- 2016-12-21 SG SG10202005670TA patent/SG10202005670TA/en unknown
- 2016-12-21 AU AU2016378721A patent/AU2016378721B2/en active Active
- 2016-12-21 SG SG11201804765UA patent/SG11201804765UA/en unknown
- 2016-12-21 WO PCT/US2016/068030 patent/WO2017112775A1/en active Application Filing
- 2016-12-21 MD MDE20181060T patent/MD3394103T2/en unknown
- 2016-12-21 DK DK16826557.7T patent/DK3394103T3/en active
- 2016-12-21 HR HRP20231156TT patent/HRP20231156T1/en unknown
- 2016-12-21 EP EP16826557.7A patent/EP3394103B1/en active Active
- 2016-12-21 HU HUE16826557A patent/HUE063377T2/en unknown
- 2016-12-21 CN CN201680075172.2A patent/CN108473578A/en active Pending
- 2016-12-21 PL PL16826557.7T patent/PL3394103T3/en unknown
- 2016-12-21 LT LTEPPCT/US2016/068030T patent/LT3394103T/en unknown
- 2016-12-21 PT PT168265577T patent/PT3394103T/en unknown
- 2016-12-21 MX MX2018007613A patent/MX2018007613A/en unknown
- 2016-12-21 MA MA44146A patent/MA44146B1/en unknown
- 2016-12-21 JP JP2018532781A patent/JP7126941B2/en active Active
- 2016-12-21 EA EA201891428A patent/EA201891428A1/en unknown
- 2016-12-21 KR KR1020187017751A patent/KR20180089444A/en active Search and Examination
- 2016-12-21 RS RS20230829A patent/RS64588B1/en unknown
- 2016-12-21 CA CA3009161A patent/CA3009161A1/en active Pending
- 2016-12-21 BR BR112018012801-5A patent/BR112018012801B1/en active IP Right Grant
- 2016-12-21 FI FIEP16826557.7T patent/FI3394103T3/en active
-
2018
- 2018-06-10 IL IL259924A patent/IL259924A/en unknown
- 2018-07-13 ZA ZA2018/04681A patent/ZA201804681B/en unknown
- 2018-11-06 HK HK18114163.2A patent/HK1255040A1/en unknown
-
2021
- 2021-03-24 US US17/210,860 patent/US20210214457A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3394103T3 (en) | 2023-09-04 |
| MA44146B1 (en) | 2023-10-31 |
| EP3394103B1 (en) | 2023-06-28 |
| ZA201804681B (en) | 2019-04-24 |
| WO2017112775A1 (en) | 2017-06-29 |
| PL3394103T3 (en) | 2023-11-20 |
| RS64588B1 (en) | 2023-10-31 |
| LT3394103T (en) | 2023-09-11 |
| CA3009161A1 (en) | 2017-06-29 |
| US20170174779A1 (en) | 2017-06-22 |
| MX2018007613A (en) | 2018-09-21 |
| EA201891428A1 (en) | 2018-12-28 |
| AU2016378721B2 (en) | 2024-01-11 |
| EP3394103A1 (en) | 2018-10-31 |
| SG10202005670TA (en) | 2020-07-29 |
| IL259924A (en) | 2018-07-31 |
| BR112018012801A2 (en) | 2018-12-04 |
| SI3394103T1 (en) | 2023-10-30 |
| FI3394103T3 (en) | 2023-08-30 |
| JP7126941B2 (en) | 2022-08-29 |
| MA44146A (en) | 2018-10-31 |
| HRP20231156T1 (en) | 2024-01-05 |
| JP2019503361A (en) | 2019-02-07 |
| ES2954153T3 (en) | 2023-11-20 |
| US20210214457A1 (en) | 2021-07-15 |
| MD3394103T2 (en) | 2023-11-30 |
| CN108473578A (en) | 2018-08-31 |
| PT3394103T (en) | 2023-09-04 |
| HUE063377T2 (en) | 2024-01-28 |
| BR112018012801B1 (en) | 2024-03-12 |
| HK1255040A1 (en) | 2019-08-02 |
| AU2016378721A1 (en) | 2018-07-19 |
| KR20180089444A (en) | 2018-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804765UA (en) | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer | |
| SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201805048SA (en) | Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia | |
| SG11201809554VA (en) | Methods of treating skin cancer by administering a pd-1 inhibitor | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201809669RA (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201810640RA (en) | Cd33 specific chimeric antigen receptors | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201808979UA (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
| SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201901950TA (en) | Methods of treating immune disorders using pd-1 binding proteins | |
| SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) |